** Shares of drugmaker TG Therapeutics TGTX.O rise 5.9% to $29.31 premarket
** Co forecasts preliminary Q4 net product revenue of $103.6 mln vs analysts' avg. est. of $97.69 mln - data compiled by LSEG
** Sees full-year 2024 net product revenue of $310 mln, above est. of $304.1 mln
** TGTX expects to end 2024 with cash position of about $310 mln
** Co forecasts 2025 total revenue of about $540 mln vs est. of $549.5 mln
** Up to last close, stock had risen 62.5% in past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。